STOCKHOLM – November 19, 2025. Umecrine Cognition today announced that a review article on golexanolone, a first-in-class drug candidate targeting overactive inhibitory brain signaling, has been…
STOCKHOLM – November 17, 2025. Umecrine Cognition AB today announced publication in Neuropharmacology of findings which show that early treatment with golexanolone provides sustained improvements…
STOCKHOLM – October 9, 2025 The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend an extraordinary general meeting at 2:30 p.m. on Thursday 23 October…
STOCKHOLM – September 25, 2025 The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend an extraordinary general meeting at 2:00 p.m. on Thursday 23…
STOCKHOLM – September 4, 2025. Umecrine Cognition today announced that the company has published results in the scientific journal Frontiers in Immunology, supporting a key mechanism for…
STOCKHOLM – July 14, 2025. Umecrine Cognition today announced that the company has raised SEK 24,6 million through a convertible loan with attached share options directed to a consortium of…
STOCKHOLM – May 26, 2025. Umecrine Cognition today announces that the company has informed its clinical partners and study center investigators that they may resume the inclusion of eligible…
STOCKHOLM – May 20, 2025. The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general meeting at 14:00 (CEST) on Thursday 12 June 2025 at…
STOCKHOLM – May 7, 2025. Umecrine Cognition today announces that the company will present validation and implementation data for the newly developed clinical scale CGI-S-PBC™ (Clinical Global…
STOCKHOLM – May 5, 2025. Umecrine Cognition today announces that the company has been awarded a research grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The funding will…